[go: up one dir, main page]

WO2009099553A3 - Use of kinase inhibitor in treatment of atherosclerosis - Google Patents

Use of kinase inhibitor in treatment of atherosclerosis Download PDF

Info

Publication number
WO2009099553A3
WO2009099553A3 PCT/US2009/000590 US2009000590W WO2009099553A3 WO 2009099553 A3 WO2009099553 A3 WO 2009099553A3 US 2009000590 W US2009000590 W US 2009000590W WO 2009099553 A3 WO2009099553 A3 WO 2009099553A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
treatment
kinase inhibitor
methods
cfms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/000590
Other languages
French (fr)
Other versions
WO2009099553A2 (en
Inventor
Zory Shaposhnik
Aldons J. Lusis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2009099553A2 publication Critical patent/WO2009099553A2/en
Publication of WO2009099553A3 publication Critical patent/WO2009099553A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and compositions are provided for the treatment of cardiovascular disease. In the methods of the invention, a small molecule inhibitor of cFMS is administered to a patient in a dose effective in reducing the clinical indicia of atherosclerosis.
PCT/US2009/000590 2008-02-01 2009-01-30 Use of kinase inhibitor in treatment of atherosclerosis Ceased WO2009099553A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2571108P 2008-02-01 2008-02-01
US61/025,711 2008-02-01

Publications (2)

Publication Number Publication Date
WO2009099553A2 WO2009099553A2 (en) 2009-08-13
WO2009099553A3 true WO2009099553A3 (en) 2009-12-30

Family

ID=40952598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/000590 Ceased WO2009099553A2 (en) 2008-02-01 2009-01-30 Use of kinase inhibitor in treatment of atherosclerosis

Country Status (1)

Country Link
WO (1) WO2009099553A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104529911B (en) * 2014-12-31 2017-06-23 华中农业大学 A kind of tritiated ends the preparation method of general woods
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
AU2018275891B2 (en) 2017-06-02 2025-02-27 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
KR20200054160A (en) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 Preparation and method of articles for treatment with adoptive cell therapy
AU2018291032A1 (en) 2017-06-29 2020-01-16 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US20210071258A1 (en) 2017-09-01 2021-03-11 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
IL283298B2 (en) 2018-11-30 2025-03-01 Juno Therapeutics Inc Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
AU2020395318A1 (en) 2019-12-06 2022-06-09 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating B cell malignancies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060577A1 (en) * 2005-09-14 2007-03-15 Player Mark R 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
US20070060577A1 (en) * 2005-09-14 2007-03-15 Player Mark R 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONWAY ET AL.: "Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.", PNAS, vol. 102, November 2005 (2005-11-01), pages 16078 - 16083 *

Also Published As

Publication number Publication date
WO2009099553A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
EA201300121A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PREPARATION
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
IL225198A (en) Aminotetrahydropyran compounds, pharmaceutical compositions comprising the same and the use thereof for the treatment of diabetes
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UY31526A1 (en) 4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE
EA201101190A1 (en) A PHARMACEUTICAL COMPOSITION INCLUDING LINAGLIPTIN AND OPTIONAL SGLT2 INHIBITOR AND ITS APPLICATION
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
ECSP088745A (en) SUBSTITUTED DERIVATIVES OF CHROMANOL AND ITS USE
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
WO2010121675A3 (en) Thiazolyl-benzimidazoles
PL2373310T3 (en) Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics
EA201171229A1 (en) THERAPEUTIC APPLICATION OF HINAZOLINDION DERIVATIVES IN CARDIOVASCULAR DISEASES
EA201070918A1 (en) APPLICATION OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
ECSP10010711A (en) 7-SULFANILMETIL-, 7-SULFINILMETIL- AND 7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09707931

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09707931

Country of ref document: EP

Kind code of ref document: A2